Lab-Grown Insulin Cells Show Promise in Mouse Diabetes Model Through Immune Protection Mechanism

One promising approach to treating Type 1 diabetes is replacing damaged insulin-producing cells with healthy ones grown in the lab. Researchers can now create insulin-producing cells (IPCs) from human amniotic tissue—the membrane surrounding a developing fetus. However, two major problems have blocked this strategy from becoming a practical treatment: transplanted cells often don't survive long in the body, and the immune system recognizes them as foreign and attacks them.

In a new study published in the FASEB Journal, researchers tested whether boosting a specific gene called METTL3 in these lab-grown cells could solve the survival problem. They transplanted two groups of insulin-producing cells into diabetic mice: one group with normal METTL3 levels and one group with METTL3 overexpressed, or artificially increased.

Mice that received the METTL3-enhanced cells showed significantly better blood sugar control and produced more insulin than mice receiving standard cells. The enhanced cells survived longer under the kidney capsule where they were implanted, and the grafts remained functional longer overall.

The researchers investigated how METTL3 overexpression helped the transplanted cells survive. They discovered that boosting METTL3 activated a natural protection mechanism: increased production of a molecule called kynurenine through a pathway involving the protein IDO1.

Kynurenine is an immune-modulating molecule—it doesn't eliminate the immune response but rather tunes it down, reducing inflammation and immune attack on the transplanted cells. When researchers added kynurenine to regular (non-modified) transplanted cells, those cells also performed better. Conversely, blocking kynurenine in the enhanced cells reduced their survival benefit, confirming that this pathway was key to the improvement.

An unexpected finding emerged: mice receiving the modified cells not only had better-functioning transplants, but their own remaining insulin-producing cells—the ones damaged by diabetes—showed signs of protection from further damage. These endogenous islets showed reduced cell death markers and maintained higher insulin expression in the METTL3-enhanced group.

This suggests the immune-calming effect of the transplanted cells may have created a more favorable environment for the body's own damaged insulin cells, though the exact mechanism requires further study.

This mouse study demonstrates that genetic modification of lab-grown insulin cells can meaningfully improve their survival after transplantation and enhance their ability to control blood sugar. The kynurenine pathway represents a specific, targetable mechanism for immune protection that researchers can build upon.

However, this remains early-stage research. The work was conducted in mice with a specific type of induced diabetes, and results in animals do not always translate to humans. Before this approach could be tested in people, researchers would need to further optimize the technique, test safety extensively, and demonstrate the same benefits in larger animal models. Cell replacement therapy for Type 1 diabetes remains a developing field with significant promise, but clinical application is still in the future.

Source: FASEB journal : official publication of the Federation of American Societies for Experimental Biology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.